Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000596715 | SCV000701271 | pathogenic | not provided | 2016-06-01 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001072038 | SCV001237381 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2A | 2023-12-25 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 10 of the CAPN3 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CAPN3 are known to be pathogenic (PMID: 10330340, 15689361). This variant is present in population databases (rs747557404, gnomAD 0.0009%). Disruption of this splice site has been observed in individuals with autosomal recessive CAPN3-related conditions (PMID: 16650086; Invitae). ClinVar contains an entry for this variant (Variation ID: 288426). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV000596715 | SCV002018082 | pathogenic | not provided | 2020-02-26 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003463772 | SCV004213803 | pathogenic | Muscular dystrophy, limb-girdle, autosomal dominant 4 | 2023-02-20 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001072038 | SCV002085509 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2A | 2021-04-02 | no assertion criteria provided | clinical testing |